|
Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma. |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Novartis; Sigma-Tau; Takeda |
Speakers' Bureau - Merck Sharp & Dohme |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
Research Funding - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Jazz Pharmaceuticals |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
Anne-Isabelle Bertozzi-Salamon |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Apexigen; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Jazz Pharmaceuticals; Medical Learning Group |
Consulting or Advisory Role - Amgen; Amgen; eviti; Gilead Sciences; Janssen-Ortho; Jazz Pharmaceuticals; Shire |
Research Funding - GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Kite, a Gilead company (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Novartis; Roche/Genentech |
Research Funding - AstraZeneca |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Novartis; Roche/Genentech |
Other Relationship - Abbvie; Bristol-Myers Squibb; Celgene; Novartis |